Bristol Myers Squibb (BMY) Stock Price, News & Analysis

Company Overview

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. With roots tracing back to the founding of Bristol-Myers in 1887 and E.R. Squibb & Sons in 1858, the company merged in 1989 to combine decades of expertise in pharmaceutical research and development. Today, Bristol Myers Squibb concentrates on four therapeutic areas—oncology, hematology, immunology and cardiovascular disease—seeking to address unmet medical needs through both small molecules and biologics.

The company’s product portfolio includes leading therapies such as the immuno-oncology agents Opdivo and Yervoy, the blood cancer therapy Revlimid, the rheumatoid arthritis treatment Orencia, and the cardiovascular medicine Eliquis. In addition to its marketed drugs, Bristol Myers Squibb maintains a robust pipeline of clinical and preclinical candidates in areas like fibrosis, neuroscience and cell therapy. Research efforts are supported by collaborations with academic institutions and biotech partners, reflecting a commitment to science-driven innovation.

Bristol Myers Squibb operates in more than 60 countries, with major research hubs in North America, Europe and Asia, and manufacturing facilities across key regions. The company’s global footprint enables it to serve diverse patient populations and navigate complex regulatory environments. Through its network of subsidiaries and joint ventures, Bristol Myers Squibb also strives to improve patient access to therapies in emerging markets and under-resourced communities.

Under the leadership of Chairman and Chief Executive Officer Giovanni Caforio, M.D., Bristol Myers Squibb emphasizes strong corporate governance, sustainability and social responsibility. The executive team and board of directors oversee strategic initiatives aimed at enhancing research productivity, driving operational efficiency and fostering a culture of inclusivity and ethical conduct within the organization.

Key Stats

• Today's Range: $46.81 to $48.36
• 50-Day Range: $44.06 to $50.68
• 52-Week Range: $41.61 to $63.33
• Volume: 16.47 million shs
• Average Volume: 12.80 million shs
• Market Capitalization: $97.82 billion
• P/E Ratio: 18.00
• Dividend Yield: 5.16%
• Price Target: $57.69
• Consensus Rating: Hold

Bristol Myers Squibb Stock Analysis - MarketRank™

Bristol Myers Squibb scored higher than 98% of companies evaluated by MarketBeat, and ranked 30th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Bristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.32, and is based on 5 buy ratings, 13 hold ratings, and 2 sell ratings.

Amount of Analyst Coverage

Bristol Myers Squibb has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -9.64%

Earnings Growth

Earnings for Bristol Myers Squibb are expected to decrease by -9.64% in the coming year, from $6.74 to $6.09 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bristol Myers Squibb is 18.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bristol Myers Squibb is 18.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.07.

Price to Earnings Growth Ratio

Bristol Myers Squibb has a PEG Ratio of 2.43. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Bristol Myers Squibb has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.94% of the float of Bristol Myers Squibb has been sold short.

Short Interest Ratio / Days to Cover

Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bristol Myers Squibb has recently increased by 17.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Bristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 5.26%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Bristol Myers Squibb has been increasing its dividend for 17 years.

Dividend Coverage

The dividend payout ratio of Bristol Myers Squibb is 92.88%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 40.72% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -2.30

Percentage of Shares Shorted

1.94% of the float of Bristol Myers Squibb has been sold short.

Short Interest Ratio / Days to Cover

Bristol Myers Squibb has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bristol Myers Squibb has recently increased by 17.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.52

News Sentiment

Bristol Myers Squibb has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.95 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 73 news articles for Bristol Myers Squibb this week, compared to 40 articles on an average week.

Search Interest

124 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.

MarketBeat Follows

21 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 5% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Bristol Myers Squibb insiders have bought 5,384.54% more of their company's stock than they have sold. Specifically, they have bought $202,215.00 in company stock and sold $3,687.00 in company stock.

Percentage Held by Insiders

Only 0.09% of the stock of Bristol Myers Squibb is held by insiders.

Percentage Held by Institutions

76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BMY Stock Analysis - Frequently Asked Questions

How have BMY shares performed this year?

Bristol Myers Squibb's stock was trading at $56.56 at the start of the year. Since then, BMY shares have decreased by 15.0% and is now trading at $48.0650.

How were Bristol Myers Squibb's earnings last quarter?

Bristol Myers Squibb Company (NYSE:BMY) announced its earnings results on Thursday, April, 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company's revenue was down 5.6% on a year-over-year basis.
Read the conference call transcript.

When did Bristol Myers Squibb's stock split?

Shares of Bristol Myers Squibb split on Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly minted shares were issued to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

How will Bristol Myers Squibb's stock buyback program work?

Bristol Myers Squibb's board authorized a stock buyback program on Thursday, December 7th 2023, which authorizes the company to repurchase $3,000,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 2.9% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its shares are undervalued.

Does Bristol Myers Squibb have any subsidiaries?

Bristol Myers Squibb subsidiaries include MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and more.

Who are Bristol Myers Squibb's major shareholders?

Top institutional shareholders of Bristol Myers Squibb include Swedbank AB (0.15%), Fort Washington Investment Advisors Inc. OH (0.13%), Kingstone Capital Partners Texas LLC (0.10%) and Douglas Lane & Associates LLC (0.08%). Insiders that own company stock include Giovanni Caforio, David V Elkins, Samit Hirawat, Christopher S Boerner, Rupert Vessey, Theodore R Samuels II, Ann Powell, Phil M Holzer, Benjamin Hickey and Robert M Plenge.
View institutional ownership trends.

How do I buy shares of Bristol Myers Squibb?

Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bristol Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include Chevron (CVX), Comcast (CMCSA), McKesson (MCK), Charles Schwab (SCHW), Edwards Lifesciences (EW), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

• Record date for 5/1 Dividend: 4/04/2025
• Ex-Dividend for 5/1 Dividend: 4/04/2025
• Last Earnings: 4/24/2025
• Dividend Payable: 5/01/2025
• Record date for 8/1 Dividend: 7/03/2025
• Ex-Dividend for 8/1 Dividend: 7/03/2025
• Today: 7/17/2025
• Next Earnings (Estimated): 7/31/2025
• Dividend Payable: 8/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:BMY
• CIK: 14272
• Web: www.bms.com
• Phone: (212) 546-4000
• Fax: 212-546-4020
• Employees: 34,100
• Year Founded: 1887

Price Target and Rating

• Average Price Target for Bristol Myers Squibb: $57.69
• High Price Target: $73.00
• Low Price Target: $34.00
• Potential Upside/Downside: +20.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.32
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.67
• Trailing P/E Ratio: 17.90
• Forward P/E Ratio: 7.08
• P/E Growth: 2.39
• Net Income: -$8.95 billion
• Net Margins: 11.38%
• Pretax Margin: 12.82%
• Return on Equity: 87.62%
• Return on Assets: 15.98%

Debt

• Debt-to-Equity Ratio: 2.65
• Current Ratio: 1.28
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $47.64 billion
• Price / Sales: 2.04
• Cash Flow: $6.05 per share
• Price / Cash Flow: 7.89
• Book Value: $8.08 per share
• Price / Book: 5.91

Miscellaneous

• Outstanding Shares: 2,035,081,000
• Free Float: 2,033,249,000
• Market Cap: $97.14 billion
• Optionable: Optionable
• Beta: 0.36